REFERENCES

1. Agarwal, S., Desai, S., Holcomb, M. and Oberoi, A. et al (2001) 'Unlocking the value of Big Pharma',*The McKinsey Quarterly*, No. 2.pp. 65-73.

2. Annas., George J (2009). 'Globalized Clinical Trials and Informed Consent', *New England Journal of Medicine*,. 360:2050-2053.

3. Benatar SR, Singer PA et al (2000) A new look at international research ethics. BMJ; 321(7264):824–6.

4. Bernhofen, D.M. & Opie, A. (1997), Thinking teams thinking clients: issues of discourse and representation in the work of health care teams. *Sociology of Health and Illness*, *19*(3), 259–280.

5. Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor et al (2013)."introduction of therapeutics "Basic & Clinical Pharmacology, 11th Edition.

6. Butler G (2002). Strategic trends facing the pharmaceutical industry and their implications for marketing skills development. *International Journal of Medical Marketing,* 3(1):65–68.

7. Christine M. Thorp (2008), "Pharmacology and health care professionals, Pharmacology for the Health Care Professions.

8. De Smet, P.A. (1995) Should herbal medicine-like products be licensed as medicines? *Br. med. J*., 310, 1023–1024.

9. Divya Christopher, Miss Arishma (2013), "Pharmaceutical Mergers and Acquisitions" *International Journal of Advanced Research* Volume 1, Issue 5, 119-130.

10.Duggal, Ravi (2007), : Public Health Expenditures, Investment and Financing Under the Shadow of a Growing Private Sector, *Economic and Political Weekly*, 27–34.

11. Ellis, Randall, Alam, Moneer and Gupta, Indrani, (2000), Health Insurance in India - Prognosis and Prospectus, *Economic and Political Weekly*, Jan.22, 2000.

12. Foster S. Herbal medicine: an introduction for pharmacists. *NARD J*. 1996; 10: 127–44.

13. Geetanjali M, APGD, (2013), *Imperial Institute of Clinical Research*, Hazaribag, Jharkhand, India, January 22, 2013; Published January 27.

14. George Pulikuthiyil, Sunil Kumar, Gopakumar Thampi et al (2008).“Regulation of Drug and Clinical Trials in India” and Moin D. Clinical trials and safety reporting under Schedule Y. *www. pharmabiz.com.*

15. Gregson, B., Cartlidge, A. & Bond, J. (1991), *Interprofessional collaboration in primary health care organizations*. Occasional Paper 52. London: Royal College of General Practitioners.

16.Hafeez Ullah Khan, Rai Muhammad Sarfraz, Asif Mahmood, Safirah Maheen, Alamgeer, et al (2013), Emerging trends of unethical pharmaceutical marketing in Pakistan. *Indo American Journal of Pharmaceutical Research*,Vol 3, Issue 10.

17. Irfan khan pathan, Suresh nuthakki, baburao chandu, srikanth nama, et al(*2012*).“Present scenario of clinical trials in india*” IJRPC* , 2(2).

18. Josef Bednarik(2005)."Does brand differentiate pharmaceuticals?" *Neuroendocrinology Letters No.6* December Vol.26, 2005.

19. Kavitha.R (2012) ; "Health Care Industry in India" *International Journal of Scientific and Research Publications,* Volume 2, Issue 8.

20. Kraft, K. (1999) Herbal medicine products and drug law. *Forsch. Komplementärmed.*, **6**, 19–23.

21. Lisa A. Sanchez (2008)."Pharmacoeconomics: Principles, Methods, and Applications” Pharmacotherapy A Pathophysiologic Approach Seventh Edition.

22.Mahal A, Singh J, Afridi F, Lamba V, Gumber A.et al (2001). Benefits from public health spending in India, New Delhi: National Council of Applied Economic Research.

23. Nundy S, Gulhati CM (2005), A new colonialism? Conducting clinical trials in India. *N Engl J Med*; 352(16):1633–6.

24. Petryna A. et al. (2006), Global Pharmaceuticals: Ethics, Markets and Practices , Duke University Press, Zaveri N.B (1998), Patents for Medicine, Indian Drug Manufacturers‘ Association, Mumbai.

25. Poortinga, W (2006), “Social Relations or Social Capital? Individual and Community Health Effects of Bonding Social Capital”, *Social Science & Medicine*, Vol. 63, No. 1, pp. 255-270.

26. Ramaiah Itumalla., Acharyulu (2012), Indian Health care and Foreign Direct Investment: Challenges and Opportunities, *Asia Pacific Journal of Marketing & Management Review*, Vol.1 No. 2, October 2012.

27. Rao M., D.R. Krishna, A.K. Shiva Kumar, M. Chatterjee, and T. Sundararaman (2011), - Human Resources for Health in India, in *The Lancet* series, *India: Towards Universal Health Coverage*, pp. 80-91.

28. Rao, M.G., and M. Choudhury (2012), Inter-State Equalization of Health Expenditures in Indian Union, Monograph*, National Institute of Public Finance and Policy*.

29. Rao Sujatha (2004) ; Health insurance concepts and challenges *“Economic and Political weakly*” Volume I.

30.Ravi Duggal, Sunil Nandraj and Asha Vadair et al (1995*),* Health Expenditure Across States Part-I *Economic & Political Weekly*, Vol. XXX, No.15, pp.834-844.

31. Sarvamangala R, An Analytical Study of Foreign Direct investment in India health Care Sectors*, Indian Journal of Applied Research*, (2013), 3(1), 16-17.

32. Shayne Cox Gad (2009). "clinical Trials Handbook, "clinical Trials Handbook "*.John Wiley and Sons.* p.118. ISBN 0-471-21388-8.

33. Srinivasan S. (2007) Indian guinea pigs for sale: outsourcing clinical trials.(2007), *www. indiaresource.org.*

35. Tyler VE.(2003) he honest herbal. 3d ed. New York: *Pharmaceutical Products Press*.

34.Vasavi.P and Kpl Sravanthi (2013) "Evolution of health insurance in india"*: Abhinav* Volume 2.

35.Vishnu Prakash Mishra, Rohit Kumar Vishwakarma et al. (2013) "Changing Landscape in Marketing Strategies of Indian Pharmaceutical Industry" *International Journal in Multidisciplinary and Academic Research* Vol. 2, No. 6.

36. Viswanath, K., W. Randolph Steele and J.R. Finnegan (2006), “Social Capital and Health: Civic Engagement, Community Size, and Recall of Health Messages”, *American Journal of Public Health*, Vol. 96, No. 8, pp. 1456-1461.

37. National Sample Survey Organization. Department of Statistics GOI.42nd and 52nd Round.

38. Objective information about herbal products can be obtained in publications such as *Alternative Medicine Alert* (800-688-2421) and *Review of Natural Products* (314-216-2100).